Life sciences company ChromaDex Corp. (NASDAQ:CDXC) announced a partnership with MyPharma2Go, an American firm focused on Brazil and Latin America, to launch its anti-aging compounds Tru Niagen and Tru Niagen PRO in Brazil.
MyPharma2Go operates an eCommerce platform that allows patients to purchase international medicines and supplements and monitor their shipping process from origin to delivery.
The deal for the cross-border distribution strategy makes Brazil the first Latin American country to get access to Tru Niagen, CDXC said.
“This moment marks a milestone as we amplify global growth plans for Tru Niagen®. We look forward to continuing our partnership with the wonderful MyPharma2Go team on this Brazil cross-border strategy,” Chief Executive of CDXC Rob Fried added.
In August, CDXC shares fell after the company’s Q2 2022 results, which fell short of Street forecasts for revenue with a ~6% YoY decline in Tru Niagen sales.